Ea Wehler

Economic burden of toxicities associated with treating metastatic melanoma in eight countries.

BackgroundInformation on costs of managing adverse events (AEs) associated with current treatments in metastatic melanoma is limited. This study estimates costs of AEs in eight countries: Australia (AU), Canada (CA), France (FR), Germany (GE), Italy (IT), the Netherlands (NL), Spain (ES), and the UK.MethodsA literature search was conducted to identify grade 3/4 AEs from product label, published trials, conference abstracts, and treatment guidelines. Resource utilization for the management of each type of AE was determined via interviews with 5 melanoma clinicians in each country. Outpatient and inpatient costs were estimated for each type of AE using country-specific tariffs or government/published sources.ResultsIn outpatient settings, the most costly AEs per incident included cutaneous squamous cell carcinoma (CSCC) (€1063, £720; NL/UK), anemia (€1443, €1329, €1285; ES/IT/FR), peripheral neuropathy (€1289; ES), and immune-related diarrhea (AUS

Cost Effectiveness Analysis of A Flash Glucose Monitoring System for Type 1 Diabetes (T1DM) Patients Receiving Intensive Insulin Treatment in Europe and Australia

1,121; AU). In inpatient settings, the most costly AEs per hospitalization included hypophysitis (€10,265; €5316; CAN

Estimating the Economic Impact of Radium Ra 223 Dichloride (Radium-223) in Treatment of Castration-Resistant Prostate Cancer (CRPC) with Symptomatic Bone Metastases and No Known Visceral Metastatic Disease

9735; AUS

Estimating the Budget Impact of Switching from Bortezomib Intravenous (Iv) to Bortezomib Subcutaneous (Sq) in the Treatment of Relapsed/Refractory Multiple Myeloma (Mm) in Mexico.

7231: ES/FR/CA/AU), dyspnea (€9077; GE), elevated liver enzymes (€6913, CAN

The Cost-effectiveness of a Flash Glucose Monitoring System for Management of Patients with Type 2 Diabetes Receiving Intensive Insulin Treatment in Sweden

8030, AUS

Cost-Effectiveness of A Flash Glucose Monitoring System Based On Real-World Usage For Type 2 Diabetes (T2DM) Patients Using Intensive Insulin: A Swedish Perspective

6594; FR/CA/AU), CSCC (CAN

Comparative Landscape Assessment Of Us Healthcare Databases For Use In Health Economics Modeling

8934; CA), peripheral neuropathy (€6977, €4144, CAN

A Budget Impact Model Estimating the Financial Impact of Increased Use of Generic Bortezomib Intravenous (Iv) in the Treatment of Relapsed/Refractory Multiple Myeloma (Mm) in Venezuela

9472; NL/ES/CA), and diarrhea (£4284, €4113; UK/ES).ConclusionsCosts of managing AEs can be significant, and thus effective treatments with lower rates of severe AEs would be valuable.